Agios Pharmaceuticals
↗Cambridge, USA
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on pioneering therapies for rare diseases, specifically in the field of cellular metabolism and pyruvate kinase (PK) activation. The company is a leader in treating genetically defined hemolytic anemias, including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
Originally founded with a focus on oncology, Agios underwent a significant strategic shift in 2021 by selling its oncology business to Servier for $1.8 billion. Since then, the company has concentrated its resources on its rare disease portfolio, anchored by its lead product mitapivat (branded as PYRUKYND and AQVESME), which targets the underlying metabolic causes of anemia.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$35M-$50M
Founded:2008
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$1.1B+
Investors:Third Rock Ventures, Flagship Pioneering, ARCH Venture Partners, Royalty Pharma
STOCK
Exchange:NASDAQ
Ticker:AGIO
Market Cap:$1.55B
PIPELINE
Stage:Commercial
Lead Drug Stage:Approved
Modalities:Small molecule, siRNA
Active Trials:12
Trial Phases:Phase 1: 3 | Phase 2: 4 | Phase 3: 5
FDA Approvals:2
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:Royalty Pharma (Royalty financing for mitapivat), Servier (Oncology divestiture and milestone payments), NewBridge Pharmaceuticals (Distribution in GCC region)
COMPETITION
Position:Leader
Competitors:Bluebird Bio, CRISPR Therapeutics, Bristol Myers Squibb, Vertex Pharmaceuticals, Global Blood Therapeutics (Pfizer)
LEADERSHIP
Key Executives:
Brian Goff - CEO
Sarah Gheuens - Chief Medical Officer & Head of R&D
Cecilia Jones - CFO
Scientific Founders:Lewis Cantley, Tak Mak, Craig Thompson
Board Members:Brian Goff, John Maraganore, Jay Backstrom, Paul Clancy
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Agios Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.